Troponin level at presentation as a prognostic factor among patients presenting with non-ST-segment elevation myocardial infarction.
NSTEMI
troponin
Journal
Clinical cardiology
ISSN: 1932-8737
Titre abrégé: Clin Cardiol
Pays: United States
ID NLM: 7903272
Informations de publication
Date de publication:
19 Oct 2023
19 Oct 2023
Historique:
revised:
17
08
2023
received:
01
05
2023
accepted:
26
09
2023
medline:
20
10
2023
pubmed:
20
10
2023
entrez:
20
10
2023
Statut:
aheadofprint
Résumé
Timely reperfusion within 120 min is strongly recommended in patients presenting with non-ST-segment myocardial infarction (NSTEMI) with very high-risk features. Evidence regarding the use of high-sensitivity cardiac troponin (hs-cTn) concentration upon admission for the risk-stratification of patients presenting with NSTEMI to expedite percutaneous coronary intervention (PCI) and thus potentially improve outcomes is limited. All patients admitted to a tertiary care center ICCU between July 2019 and July 2022 were included. Hs-cTnI levels on presentaion were recorded, dividing patients into quartiles based on baseline hs-cTnI. Association between initial hs-cTnI and all-cause mortality during up to 3 years of follow-up was studied. A total of 544 NSTEMI patients with a median age of 67 were included. Hs-cTnI levels in each quartile were: (a) ≤122, (b) 123-680, (c) 681-2877, and (d) ≥2878 ng/L. There was no difference between the initial hs-cTnI level groups regarding age and comorbidities. A higher mortality rate was observed in the highest hs-cTnI quartile as compared with the lowest hs-cTnI quartile (16.2% vs. 7.35%, p = .03) with hazard ratio (HR) for mortality of 2.6 (95% confidence interval [CI]: 1.23-5.4; p = .012) in the unadjusted model, and HR of 2.06 (95% CI: 1.01-4.79; p = .047) with adjustment for age, gender, serum creatinine, and significant comorbidities. Patients with NSTEMI and higher hs-cTnI levels upon admission faced elevated mortality risk. This underscores the need for further prospective investigations into early reperfusion strategies' impact on NSTEMI patients' mortality, based on admission troponin elevation.
Sections du résumé
BACKGROUND
BACKGROUND
Timely reperfusion within 120 min is strongly recommended in patients presenting with non-ST-segment myocardial infarction (NSTEMI) with very high-risk features. Evidence regarding the use of high-sensitivity cardiac troponin (hs-cTn) concentration upon admission for the risk-stratification of patients presenting with NSTEMI to expedite percutaneous coronary intervention (PCI) and thus potentially improve outcomes is limited.
METHODS
METHODS
All patients admitted to a tertiary care center ICCU between July 2019 and July 2022 were included. Hs-cTnI levels on presentaion were recorded, dividing patients into quartiles based on baseline hs-cTnI. Association between initial hs-cTnI and all-cause mortality during up to 3 years of follow-up was studied.
RESULTS
RESULTS
A total of 544 NSTEMI patients with a median age of 67 were included. Hs-cTnI levels in each quartile were: (a) ≤122, (b) 123-680, (c) 681-2877, and (d) ≥2878 ng/L. There was no difference between the initial hs-cTnI level groups regarding age and comorbidities. A higher mortality rate was observed in the highest hs-cTnI quartile as compared with the lowest hs-cTnI quartile (16.2% vs. 7.35%, p = .03) with hazard ratio (HR) for mortality of 2.6 (95% confidence interval [CI]: 1.23-5.4; p = .012) in the unadjusted model, and HR of 2.06 (95% CI: 1.01-4.79; p = .047) with adjustment for age, gender, serum creatinine, and significant comorbidities.
CONCLUSIONS
CONCLUSIONS
Patients with NSTEMI and higher hs-cTnI levels upon admission faced elevated mortality risk. This underscores the need for further prospective investigations into early reperfusion strategies' impact on NSTEMI patients' mortality, based on admission troponin elevation.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.
Références
Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. JAMA. 2022;327(7):662-675. doi:10.1001/jama.2022.0358
Case BC, Yerasi C, Wang Y, et al. Admissions rate and timing of revascularization in the United States in patients with non-ST-elevation myocardial infarction. Am J Cardiol. 2020;134:24-31. doi:10.1016/j.amjcard.2020.08.010
Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-177. doi:10.1093/eurheartj/ehx393
Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-1367. doi:10.1093/eurheartj/ehaa575
Wanamaker BL, Seth MM, Sukul D, et al. Relationship between troponin on presentation and in-hospital mortality in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. J Am Heart Assoc. 2019;8(19):e013551. doi:10.1161/JAHA.119.013551
Neumann JT, Twerenbold R, Ojeda F, et al. Application of high-sensitivity troponin in suspected myocardial infarction. N Engl J Med. 2019;380(26):2529-2540. doi:10.1056/NEJMoa1803377
Nguyen TL, Phan JAK, Hee L, et al. High-sensitivity troponin T predicts infarct scar characteristics and adverse left ventricular function by cardiac magnetic resonance imaging early after reperfused acute myocardial infarction. Am Heart J. 2015;170(4):715-725.e2. doi:10.1016/j.ahj.2015.06.022
Blankenberg S, Salomaa V, Makarova N, et al. Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. Eur Heart J. 2016;37(30):2428-2437. doi:10.1093/eurheartj/ehw172
Roos A, Edgren G, Holzmann MJ. Unstable angina pectoris with myocardial injury versus myocardial infarction in the era of high-sensitivity cardiac troponin. Am J Cardiol. 2022;169:32-41. doi:10.1016/j.amjcard.2021.12.044
López-Fernández S, Cequier Á, Iràculis E, et al. Las elevaciones importantes de troponina I en el síndrome coronario agudo sin elevación del segmento ST se asocian a estenosis coronarias más complejas. Rev Esp Cardiol. 2004;57(4):291-298.
Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009;360(21):2165-2175. doi:10.1056/NEJMoa0807986
Kofoed KF, Kelbaek H, Hansen PR, et al. Early versus standard care invasive examination and treatment of patients with non-ST-segment elevation acute coronary syndrome. Circulation. 2018;138(24):2741-2750. doi:10.1161/CIRCULATIONAHA.118.037152
Koerbin G, Abhayaratna WP, Potter JM, et al. Effect of population selection on 99th percentile values for a high sensitivity cardiac troponin I and T assays. Clin Biochem. 2013;46(16):1636-1643. doi:10.1016/j.clinbiochem.2013.08.004
Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med. 1996;335(18):1333-1342. doi:10.1056/NEJM199610313351801
Kontos MC, Shah R, Fritz LM, et al. Implication of different cardiac troponin I levels for clinical outcomes and prognosis of acute chest pain patients. J Am Coll Cardiol. 2004;43(6):958-965. doi:10.1016/j.jacc.2003.10.036
Bagai A, Huang Z, Lokhnygina Y, et al. Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization. Circ Cardiovasc Interv. 2015;8(6):e002314. doi:10.1161/CIRCINTERVENTIONS.115.002314
Bjurman C, Larsson M, Johanson P, et al. Small changes in troponin T levels are common in patients with non-ST-segment elevation myocardial infarction and are linked to higher mortality. J Am Coll Cardiol. 2013;62(14):1231-1238. doi:10.1016/j.jacc.2013.06.050
Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996;335(18):1342-1349. doi:10.1056/NEJM199610313351802
Sutton MGSJ, Sharpe N. Left ventricular remodeling after myocardial infarction. Circulation. 2000;101(25):2981-2988. doi:10.1161/01.CIR.101.25.2981
Goldberger N, Aburbeh M, Haklai Z. Leading Causes of Death in Israel 2000-2019. Israel Health Information Division, Ministry of Health; 2022.